XMMEN-OE5 [AAB-647, AAB647]
XMMEN-OE5 [AAB-647, AAB647]
规格:
货期:
编号:TS210643
品牌:Testobio
| 产品名称： | XMMEN-OE5 AAB-647, AAB647 |
|---|---|
| 商品货号： | TS210643 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain： | Strain:xa0 BALB/c (B cell); BALB/c (myeloma) |
| Applications： | The antibody neutralizes gram negative endotoxin activity, and is protective against gram negative sepsis and therapeutic for gram negative sepsis in mice and humans. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with P3X63Ag8.653 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against lipopolysaccharide endotoxin of gram negative bacteria |
| Cellular Products： | immunoglobulin; monoclonal antibody; against lipopolysaccharide endotoxin of gram negative bacteria |
| Tumorigenic： | Yes |
| Effects： | Yes, forms ascites in pristane primed BALB/c mice |
| Comments： | Animals were immunized with killed E. coli (0111 strain, J5 mutant) cells. Spleen cells were fused with P3X63Ag8.653 myeloma cells. The antibody neutralizes gram negative endotoxin activity, and is protective against gram negative sepsis and therapeutic for gram negative sepsis in mice and humans. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | culture medium, 90%; DMSO, 10% |
| Isotype： | IgM |
| Name of Depositor： | Regents of the University of California |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| U.S. Patent Number： | |
| References： | Young LS. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria. US Patent 4,918,163 dated Apr 17 1990 |
首页 >
产品中心
>
微生物培养
>
菌株
>
null
>
XMMEN-OE5 [AAB-647, AAB647]
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | XMMEN-OE5 AAB-647, AAB647 |
|---|---|
| 商品货号： | TS210643 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain： | Strain:xa0 BALB/c (B cell); BALB/c (myeloma) |
| Applications： | The antibody neutralizes gram negative endotoxin activity, and is protective against gram negative sepsis and therapeutic for gram negative sepsis in mice and humans. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with P3X63Ag8.653 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against lipopolysaccharide endotoxin of gram negative bacteria |
| Cellular Products： | immunoglobulin; monoclonal antibody; against lipopolysaccharide endotoxin of gram negative bacteria |
| Tumorigenic： | Yes |
| Effects： | Yes, forms ascites in pristane primed BALB/c mice |
| Comments： | Animals were immunized with killed E. coli (0111 strain, J5 mutant) cells. Spleen cells were fused with P3X63Ag8.653 myeloma cells. The antibody neutralizes gram negative endotoxin activity, and is protective against gram negative sepsis and therapeutic for gram negative sepsis in mice and humans. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | culture medium, 90%; DMSO, 10% |
| Isotype： | IgM |
| Name of Depositor： | Regents of the University of California |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| U.S. Patent Number： | |
| References： | Young LS. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria. US Patent 4,918,163 dated Apr 17 1990 |
